Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Glenmark Pharmaceuticals Ltd reported Revenues for Q2FY24 of ₹3,207.00 Crores up from ₹3,018.00 Crore year on year, a rise of 6.26%.
Total Expenses for Q2FY24 of ₹3,007.00 Crores up from ₹2,768.00 Crores year on year, a rise of 8.63%.
Consolidated Net Profit of -₹62.00 Crores from ₹279.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹2.90, from ₹9.23 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.